Royalty Pharma (RPRX) Amortization - Intangibles (2019 - 2022)

Royalty Pharma has disclosed Amortization - Intangibles across 4 years of filings, most recently posting $5.7 million for Q1 2022.

• Amortization - Intangibles for Q1 2022 came in at $5.7 million, changed 0.02% year-over-year; the trailing twelve-month figure through Dec 2022 was $5.7 million (down 75.34% YoY), and the FY2022 annual result was $5.7 million, down 75.34% from the prior year.
• Amortization - Intangibles came in at $5.7 million for Q1 2022 at Royalty Pharma, down from $5.8 million in the prior quarter.
• In the past five years, Amortization - Intangibles ranged from a high of $5.8 million in Q3 2019 to a low of $5.7 million in Q1 2022.
• The 4-year median for Amortization - Intangibles is $5.8 million (2019), against an average of $5.8 million.
• Across the five-year window, Amortization - Intangibles changed 0.0% in 2020 and retreated 1.08% in 2021, its largest moves.
• Royalty Pharma's Amortization - Intangibles stood at $5.8 million in 2019, then changed by 0.0% to $5.8 million in 2020, then changed by 0.0% to $5.8 million in 2021, then slipped by 2.17% to $5.7 million in 2022.
• The last three Amortization - Intangibles figures came in at $5.7 million (Q1 2022), $5.8 million (Q4 2021), and $5.8 million (Q3 2021), per Business Quant data.